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INTRODUCTION 
The first liver transplant in a human was performed by Dr. 
Thomas Starzl on March 1, 1963. 1 That patient died, ClS did the 
next four patients over the next seven months. Attempts by other 
surgeons in the United States and around the world also failed, 
until a moratorium on clinical trials was called, lasting until 1966. 
Not until July 23, 1967, was the first successful liver transplant in a 
human performed-again by Dr. Starzl. The patient was an 18-
month-old girl with a hepatocellular carcinoma. She survived 13 
months before succumbing to metastases from her original disease.: 
During t,he 1960s a,nd 19705, the pace of liver transplantation was 
slowbu{,steadr as the techniques "of surgical and medical care were 
refined.3 /1 
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FIGURE .5.1. Number of liver transplants (children and adults) per-
formed by Dr, Thomas Starzl and/or associates per year, 1981 to 1984 
represents the Pittsburgh experience. 
In 1968, Roy CaIne and Roger Williams of Cambridge Univer-
sity and University of London, respectively, embarked on another 
successful liver transplant program and added additional cases for 
study.' However, it was not until the advent in 1979 of a new 
immunosuppressive agent, cyclosporine, that the number of cases 
as well as the number of survivors began to climb. From 1963 to 
1979,170 patients had livers transplanted in Denver by Dr. Starz!.J 
From 1981 to the end of 1984, the effort in Pittsburgh exceeded 
the entire Denver experience (Figure 5.1). Because of the pioneering 
work by Dr. Starzl and others and because of the improved survival 
rate due in part to the use of cyclosporine, other centers in the 
United States and around the world are establishing liver transplant 
facilities. 
This chapter summarizes the experience with pediatric liver 
transplantation at the Children's Hospital of Pittsburgh from May 
1981 through May 1984. 
HARVESTING AND GRAFTING 
A brief review of donor harvesting and organ grafting is 
presented only to maintain continuity. Details of these techniques 
can be found in other references.J Ideally, the donor is brain-dead, 
with a stable cardiovascular system during external support. Donors 
are usually accident victims. 
When a donor is found, a team is sent to the donor's hospital 
and preparations made for harvesting. With respiratory and circu-
latory support for the donor, a midline incision is made and struc-
tures entering and exiting the liver are skeletonized. The liver is 
flushed in situ with a cold electrolyte solution, the cadaver is 
exsanguinated, and the liver is removed. It is placed in a sterile 
plastic bag, packed in slushed ice, and immediately transported. 
Notably, the procedure may be altered to accommodate harvesting 
the kidneys as well as the heart. Time is of the essence; the 
maximum cold ischemia time is only 8-12 h. J 
While the donor organ is being harvested, another surgical 
team is preparing the recipient for transplantation. The recipient's 
hepatectomy may be difficult in the face of multiple previous 
abdominal operations, coagulation abnormalities, and massive col-
lateral vessels. The structures surrounding the liver ate skeleton-
ized while the donor liver is en route. The timing-of the reCipient's 
surgery is coordinated with the harvesting team, so that on the 
organ's arrival the transplant may proceed with minimal delay. 
'The vessels and bile duct are clamped and transected. The 
liver is removed and the donor organ placed for grafting. The 
vascular anastomoses are completed and the biliary anastomosis 
performed. A bile duct to a Roux limb of jejunum is used in most 
children, especially those with biliary atresia. Whenever possible, a 
duct-to-duct anastomosis is performed. 
IMMUNOSUPPRESSION 
Constraints of cold ischemia time do not allow systematic 
HLA matching between the donor and recipient. In general, the 
donor and recipient are matched according to size and ABO blood 
group.' In part, this is permitted because the liver appears to be 
resistan~to hyperacute rejection d<r~pitbl the presence of preformed 
antibody.s 1/ 
64 I Basil J. Zitelli, et al. 
TABLE 5.1. Major Side Effects of Cyclosporine 
Nephrotoxicity 
Hepatotoxicity 
Hirsutism 
Tremor 
Seizures 
Gingival hyperplasia 
Skin flushing 
Breast fibroadenomata 
Pseudolymphoma 
Infection 
Hypertension 
Previous immune suppression regimens included prednisone, 
azothiaprine, cyclophosphamide, antilymphocyte globulin, and 
thoracic duct drainage. Each of these regimens was attended by 
numerous complications, including bone-marrow suppression and 
infection. In addition, massive doses of steroids were often required 
to keep rejection in check, and these doses were associated with 
complications such as Cushingoid features, hypertension, and linear 
growth retardation. 
Caine first reported the use of a new immunosuppressant, 
cyclosporine, in humans in 1978.6 A fungal extract discovered by 
scientists at the Sandoz Laboratories in Switzerland, cyclosporine 
was noted to be a powerful immunosuppressant but had little or 
no bone-marrow suppression. 7 Cyclosporine selectively and revers-
ibly affected T-cell function. As with any drug, however, cyclos-
porine has its own attendant toxicities (Table 5.1). Each of the 
effects, including the pseudolymphoma, is believed to be reversible 
by lowering the dose or temporarily stopping the drug. 1I 
Intravenous cyclosporine is given immediately preoperatively, 
and maintained postoperatively at an initial dose of 6 mg/kg/day. 
Oral cyclosporine is also given when the patient is able to take 
medication enterally, and is overlapped with intravenous cyclo-
sporine. A burst of steroids is given in the perioperative period and 
is rapidly weaned over 4-5 days to a baseline daily dose of 20 mg of 
prednisone. When liver functions normalize, the intravenous cy-
closporine is weaned. As liver functions stabilize, the prednisone 
dose is gradually reduced to a minimum of 2.5-5 mg/day. On this 
regimen, most children have been able to grow and develop with 
little or no long-term steroid complications. 
Rejection may be manifested clinically by fever, malaise, vague 
abdominal pain, hepatomegaly, and ascites, accompanied by a rise 
in bilirubin, transaminases, alkaline phosphatase, and gamma glu-
~a~yl tr~~speptidaseK Rejection can be confused with ischemic' 
fnI~ryI b"~ary obstruction, cholangitis, viral hepatitis, or drug 
~lulcltyK1t IS treated with boluses of steroids as well as adjustments 
In the cyc/osporine dose. 
EV ALVA nONS AND TRANSPLANTS (PITTSBURGH 
1981-1984) , 
. In a 36-month pe.riod from May 1981 to May 1984, 90 pediatric 
pa tte~ ts un~erwe~ t gK~erK transplanta tion. This is the single largest 
expenence In pedlatnc J.ver transplantation. The process began 
when a family or physician contacted us about a potential cilndidate. 
Records ~ere sent to us for review, and if the patient appeared to 
be a candidate: the family was asked to come to Pittsburgh for a 
formal evaluatIOn. Two hundred and nine patients were evaluated 
f?r transp~antK The evaluation centered on confirming the diagno-
SIS, assessing the severity and progression of the patient's liver 
dlseas~I evaluating anatomical suitability for transplantation, and 
educating the family. 
Table 5.2 lists the indications for transplantation and the 
outcome. Biliary atresia accounted for 43% of the patients trans-
planted, with various metabolic disorders (24%) compriSing the 
n~xt larg~stKgroupK Twenty-three patients died post transplantation 
With a minimum of a 6-month follow-up, giving a 74% survival 
rate. 
COMPLICA nONS 
. ~he s~rDgery and postoperative period are fraught with com-
pJ.cahons. Table 5.3 summarizes the primary and secondary causes 
?f dea.th In 23 pa~ientsK Rejection and its complications as well as 
mfe~tlon (lncludmg overwhelming varicella in 1 patient) were 
leadmg caus~s of de~thK Vascular complications, including throm-
bosed hepatic artenes or preexisting anomalies such as absent 
portal ~ein 9r anomal?~s venous drai~age of the upper body, led to 
deathsm at/lather 5 patients. Intracrilnial hemorrhage or cerebral 
edema led to thrAeath of 3 more patients. 
I 
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TABLE S.2. Indications for Liver Transplantation 
Biliary atresia' 
Biliary hypoplasia 
Familial cholestasis 
Hepatitis 
Neonatal hepatitis 
Metabolic disorders 
A,AT 
Tyrosinemia 
Glycogen storage 
disease I 
Sea blue histiocyte 
Hypercholesterolemia· 
Wilson's disease 
Biliary obstruction 
Benign tumor 
Idiopathic cirrhosis 
Acute hepatic failure 
') auxiliary transplant. 
°0 represents number of deaths. 
·Combined heart-liver transplant. 
15(3) 
2(0) 
1(0) 
1(0) 
1(0) 
2(1) 
39(10)" 
9(3) 
7(2) 
5(2) 
3(0) 
22(4) 
1(1) 
1(0) 
1(0) 
2(1) 
90(23) 
Myocardial infarction occurred in a patient with Alagille's 
syndrome with a partially corrected pulmonary stenosis. Hepatic 
infarction (with patent vessels) led to graft loss and patient death 
in 5 other patients. This may have been due to ischemic injury 
during harvesting or during surgery in the patients lost shortly 
TABLE 5.l. Major Factors in the 2l Deaths 
Rejection 
Vascular anomalies. preoperative 
Vascular complications, surgical 
Infection 
Massive liver infarction with 
patent vessels 
Cerebrovascular accident/edema 
Myocardial infarction 
Primary 
4 
2 
4 
4 
early 3 
late 2 
3 
1 
Suondary 
2 
1 
1 
5 
1 
Pt.i.t,.;, H,p.tDIDIY / '61 
TABLE 5.4. Early (First Two Months) Complications 
among the 67 Survivors 
Hypertension (seizures 7) 
Rejection 
Major infection 
Biliary tract (surgical) 
Prolonged tracheostomy 
Vascular thrombosis (retransplant 5) 
Renal failure (dialysis) 
Diabetes mellitus (transient) 
Myocardial infarction 
'NumMrs represent patients rather than episodes. 
66' 
46 
19'-
7 
7 
8 
3 
2 
2 
after transplant, but little explanation can be offered for 2 patients 
who had sudden infarction 10 and 11 days after the transplant. 
Complications among the survivors can be divided into early 
(less than 2 months) and late (more than 2 months), using 2 
months as a convenient dividing point. Most patients are usually 
discharged from the hospital by 2 months posttransplant. Table 
5.4 lists the early onset complications in the 67 survivors. 
Hypertension was an almost universal phenomenon occurring 
immediately posttransplant and often required multiple drug 
therapy for control. Seven patients had hypertensive encephalop-
athy with seizures. Fortunately, none has sustained serious per-
manent sequelae. Although the mechanism of the hypertension is 
unknown, it is suspected that cyclosporine may be in part respon-
sible through its stimulation of the renin-angiotensin system. 
Rejection also occurred frequently, but was usually able to be 
controlled with bursts of steroids and alteration of cyclosporine 
doses. 
Major life-threatening infections occurred in 19 patients. 
Gram-negative organisms were most frequently cultured, although 
the Staphylococcus as well as Candida sp and cytomegalovirus also 
caused significant morbidity. 
Late complications (Table 5.5) included rejection as the most 
commonly occurring among the survivors. Surgical complications 
such as portal vein obstruction occurred in 4 patients. In two 
patients, who had a portocaval shunt prior to transplantation the 
portal ~eins were thrombosed postttansplantation. Interstitial II 
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TABLE 5.5. Late (After Two Months) Complications 
among the 67 Survivors 
Rejection 
Portal vein obstruction 
Biliary tract (surgicall 
Hypertension 
Interstitial pneumonitis 
lymphoma 
Pseudotumor cerebri 
Recurrent storage disease 
Mdjllr infection 
-------_ .. 
·kumb~rK r~pr .. s .. nt pati~nts rath~r than ~pisod~s_ 
22· 
4 
2 
2 
5 
2 
pneumonitis with presumed Pnl'umocysfis carin;; occurred in 5 
patients, usually about 3-4 months posttransplant. Two patients 
developed a Iymphoproliferative disorder after a primary Epstein-
Barr virus infection. One patient presented with intestinal obstruc-
tion,S while the other presented with marked tonsillar hypertrophy 
and airway obstruction. Both patients had resection of the tumor 
(patient No.1 had only a partial resection), and cyclosporine was 
lowered. Neither patient has had evidence of recurrence of the 
tumor. 
While infections remain a major complication of the transplant 
procedure, the bone marrow-sparing qualities of cyc1osporine may 
be helpful in limiting life-threatening infections. Table 5.6 compares 
the number of episodes of bacteremia and fungemia per graft in 
the precyc1osporine era with the first 24 months of our own 
experience using cyclosporine. The number of episodes of bac-
teremia is less using cyclosporine. Fungal infections, however, 
may be slightly greater, although the number of episodes is quite 
small. While other factors such as differing surgical or medical 
regimens were not controlled in this superficial evaluation, it 
appears that cyclosporine may offer a protective advantage against 
bacteremia compared with previous immune suppression regimens. 
METABOLIC DISORDERS 
Liver transplantation provides a unique opportunity to study 
the systemic effects of hepatic-based metabolic disease. lo In the 
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TABLE 5.6 Bacteremia/Fungemia (No. of Episodes per Graft) 
P.t CYA (3/63-11174) 
Bacteremia 
Fungemia 
Total 
69/102 (67%) 
3/102 ( 3%) 
71/102 (70%) 
Post CYA (5181-5/83 
Bacteremia 
Fungemia 
Total 
29/64 (45%) 
4/64 ( 6%) 
33/64 (51%) 
precyclosporine era, patients with metabolic'disorders had a clear 
survival advantage,lJ but more recently the difference in survival 
between patients with biliary atresia, who historically had a poorer 
outcome, and children with metabolic disorders has narrowed 
significantly. Currently, the overall survival rate for all 90 patients 
is 74%. Transplanted patients with biliary atresia have a 74% 
overall survival rate, while patients with metabolic diseases have 
an 82% survival rate. 
Fifteen patients with alpha-I-antitrypsin deficiency were 
transplanted. Fourteen patients were examined postoperatively. 
All 14 patients had normalized serum alpha-I-antitrypsin levels 
and all assumed the Pi type of the donor. In addition, on examination 
of the transplanted liver in all 15 patients, no PAS positive, 
diastase-resistant granules were noted. Clinically, no patient has 
had any evidence of disease consistent with alpha-I-antitrypsin 
deficiency.12 
Two patients with Wilson's disease were transplanted. One 
survived. He was a 13-year-old boy who failed medical management 
and progressed to hepatic failure, renal failure, and coma. He had 
typical neurological findings of Wilson's disease with bradykinesia 
and cogwheel rigidity. After successful transplantation, liver 
function was normal and the hepatorenal syndrome resolved. 
Serum copper and ceruloplasmin normalized, although urinary 
copper excretion remained high. The boy's neurological function 
returned to normal over the year posttransplant. Return of neuro-
logical function has been also reported in other patients with 
Wilson's disease after successful transplantation. t3 
Two patients with tyrosinemia and hepatoma were success-
fully transplanted without evidence of recurrence of their original 
disease or tumor. In both cases, the tumor was entirely confined to 
the ,live!,. Shortly after transplantation, both patients maintained 
n~rmal IseruJP, amino acids while! on a regular diet, and are now 
Jeading virttla"ily normallives. 14 
I 
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A teenage girl with glycogen storage disease, type L had a 
history of profound hypoglycemia requiring portocaval shunting 
and continuous nighttime feedings. She developed progressive 
hepatic failure due to hemorrhage into hepatic adenomata. She 
underwent successful liver transplantation, and postoperatively 
was able to maintain a normal serum glucose during a 24-h fast. In 
addition, a brisk glycogenolytic response was demonstrated to 
parenteral glucagon administration. ls Glucose homeostasis has 
remained normal during a 3-year follow-up. However, this patient's 
portal vein was thrombosed posttransplantation, and she required 
a distal splenorenal shunt to control portal hypertension. In addi-
tion, she has had problems with serious infections including Pntu-
mocystis carinii pneumonia and Candida torulopsis meningitis. 
Homozygous familial hypercholesterolemia ravaged the heart 
of a 6-year-old Texas girl. During evaluation for her hypercholes-
terolemia, which ranged more than 1000 mg/dl, she had two 
myocardial infarctions requiring two separate double bypass 
operations and placement of an artificial mitral valve. A combined 
heart and liver transplant was performed.16 Postoperatively, cho-
lesterols fell to the 200-250 mg/dl range and plateaued at approx-
imately 300 mg/dl. In this case, replacement both of the morpholog-
ically normal liver with a subcellular metabolic defect and of the 
damaged target organ, the heart, has allowed this patient to lead a 
virtually normal life. 
The sea-blue histiocyte syndrome is a poorly understood, 
progressive degenerative neurological disorder characterized by 
the accumulation of ceroid-like material in macrophages in the 
liver and bone marrow. The marrow demonstrates a nonspecific 
sea blue histiocyte. Liver disease progresses to cirrhosis, and in our 
patient a hepatoma was also found at transplantation. Neurological 
deterioration temporarily plateaued after transplantation, but 
storage material accumulated in the transplanted organ again and 
neurological function again worsened. It appears that the metabolic 
defect in this disorder is not hepatocyte-based, and liver transplan-
tation may not be indicated. lo .17 
Overall, previously fatal hepatic-based metabolic disorders 
are potentially curable with liver transplantation. Long-term 
follow-up of these patients, however, is imperative to assure no 
recurrence of the original disease, although none is expected. In 
addition, patients and families will continue to require genetic 
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fiGURE 5.l. Comparison of survival of pediatric pati.ents wit.h cyd~­
sporine and steriods transplanted in Pittsburgh Eclo~eEf Cf~c1esF ~fth pedI-
atric patients transplanted in Denver under conventaonal Immuno-
suppression (open circles). 
counseling since their offspring may still be at risk for these 
inheritable disorders. 
FOLLOW-UP 
The pediatric survival rate under cyclosporine and steroid~ is 
compared in Figure 5.2 with the survival rate in the precyclosportne 
era. With improved surgical technique and medical management 
as well as the advent of cyclosporine, the current survival rates are 
over 74%. 
Graft function as of March 1985 is summarized in Table 5.7. 
Patients with poor graft function are awaiting retransplantation. 
TABLE 5.7. Graft Function in the 67 Survivors 
Excellent; 
Poor' ./ 
p 
No. 
6S 
2 
Bi!irllbi" (mgltlll 
0.1-1.4 
16-45 
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The quality of life for these patients is excellent postdischarge. 
More than 80% of the patients with growth potential will either 
exhibit catch-up growth or maintain a normal growth velocity. 
These patients have had fewer hospitalizations posttransplant 
compared with the pretransplant period and are able to attend 
school in appropriate age grades. Children are described by their 
parents as happier and more outgoing, and the physical stigmata 
of chronic liver disease are removed. There are still fears, however, 
of rejection and malignancy. Psychological adjustments for parents, 
patients, and siblings to the new "state of the family" may be 
difficult, and at times may lead to the vulnerable-child syndrome 
and sibling jealousy. 
Liver transplantation is arduous and at times frustrating. It 
requires a massive team effort from every level of the hospital 
staff. With close cooperation and careful coordination, however, a 
successful and rewarding program can be established. 
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